Uric acid and xanthine oxidoreductase in wound healing

Current Rheumatology Reports

Volumn 16, Issue 2, 2014, Pages

  Fernandez, Melissa L ^a   Upton, Zee ^a   Shooter, Gary K ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Inflammation; Topical allopurinol; Uric acid; Wound healing; Xanthine oxidoreductase

Indexed keywords

ALLOPURINOL; ENZYME INHIBITOR; FREE RADICAL; SCAVENGER; URIC ACID; XANTHINE DEHYDROGENASE;

CHRONIC DISEASE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VARICOSIS; WOUND HEALING;

ALLOPURINOL; CHRONIC DISEASE; ENZYME INHIBITORS; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; INFLAMMATION; URIC ACID; VARICOSE ULCER; WOUND HEALING; XANTHINE DEHYDROGENASE;

EID: 84890420151     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0396-1     Document Type: Article

References (87)

1. Cullum N et al. Compression for venous leg ulcers. Cochrane Database Syst Rev. 2000;3:CD000265.
2. Abbade LP, Lastoria S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol. 2005;44(6):449-56.
3. Simon DA, Dix FP, McCollum CN. Management of venous leg ulcers. Bmj. 2004;328(7452):1358-62.
4. Baker SR, Stacey MC. Epidemiology of chronic leg ulcers in Australia. Aust N Z J Surg. 1994;64(4):258-61.
5. Kurd SK et al. Evaluation of the use of prognostic information for the care of individuals with venous leg ulcers or diabetic neuropathic foot ulcers. Wound Repair Regen. 2009;17(3):318-25.
6. Stadelmann WK, Digenis AG, Tobin GR. Impediments to wound healing. Am J Surg. 1998;176(2A Suppl):39S-47S.
7. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312(3):159-63.
8. Fernandez, M.L., et al., Elevated uric acid correlates with wound severity. Int Wound J.
9. Montesinos MC et al. Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J Exp Med. 1997;186(9): 1615-20.
10. Montesinos MC et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol. 2002;160(6):2009-18.
11. Jiang S et al. Non-adenine based purines accelerate wound healing. Purinergic Signal. 2006;2(4):651-61.
12. Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol. 2005;67(5):1385-7.
13. Valls MD, Cronstein BN, Montesinos MC. Adenosine receptor agonists for promotion of dermal wound healing. Biochem Pharmacol. 2009;77(7):1117-24.
14. Chan ES et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in amurine model of scleroderma. Arthritis Rheum. 2006;54(8):2632-42.
15. Feoktistov I et al. Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res. 2002;90(5):531-8.
16. Khoa ND et al. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J Immunol. 2001;167(7):4026-32.
17. Hasko, G. and B. Cronstein, Regulation of inflammation by adenosine. Front Immunol. 4: p. 85.
18. Cronstein BN et al. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest. 1990;85(4):1150-7.
19. Hasko G et al. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. Eur J Pharmacol. 1998;358(3):261-8.
20. Hasko G et al. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther. 2007;113(2):264-75.
21. Sipka S et al. Adenosine inhibits the release of interleukin-1beta in activated human peripheral mononuclear cells. Cytokine. 2005;31(4):258-63.
22. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol. 1996;270(2 Pt 1): C522-9.
23. Bullough DA et al. Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes. J Immunol. 1995;155(5):2579-86.
24. Cronstein BN et al. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 1986;78(3):760-70.
25. Cronstein BN et al. Neutrophil adherence to endotheliumis enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol. 1992;148(7):2201-6.
26. Sullivan GW et al. Activation of A2A adenosine receptors inhibits expression of alpha 4/beta 1 integrin (very late antigen-4) on stimulated human neutrophils. J Leukoc Biol. 2004;75(1):127-34.
27. Desai A et al. Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Mol Pharmacol. 2005;67(5):1406-13.
28. Chen JH et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61(2):225-32.
29. Kodama S et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737-42.
30. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail. 2009;2(6):556-62.
31. Ghaemi-Oskouie, F. and Y. Shi, The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep. 13(2): p. 160-6.
32. Kippen I et al. Factors affecting urate solubility in vitro. Ann Rheum Dis. 1974;33(4):313-7.
33. Tak HK, Cooper SM, Wilcox WR. Studies on the nucleation of monosodium urate at 37 degrees c. Arthritis Rheum. 1980;23(5): 574-80.
34. Jin, M., et al., Uric acid, hyperuricemia and vascular diseases. Front Biosci (Landmark Ed). 17: p. 656-69.
35. Martinon F et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-41.
36. Halle A et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857-65.
37. Hornung V et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847-56.
38. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen. 1996;4(4):411-20.
39. Trengove NJ, Langton SR, Stacey MC. Biochemical analysis of wound fluid from nonhealing and healing chronic leg ulcers. Wound Repair Regen. 1996;4(2):234-9.
40. Trengove NJ et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 1999;7(6):442-52.
41. Shi Y,Mucsi AD, Ng G.Monosodium urate crystals in inflammation and immunity. Immunol Rev. 2010;233(1):203-17.
42. Torres R et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis. 2009;68(10):1602-8.
43. Akahoshi T et al. Prevention of neutrophil apoptosis by monosodium urate crystals. Rheumatol Int. 1997;16(6):231-5.
44. Popa-Nita, O. and P.H. Naccache, Crystal-induced neutrophil activation. Immunol Cell Biol. 88(1): p. 32-40.
45. Kono, H., et al., Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest. 120(6): p. 1939-49.
46. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452-60.
47. Ames BN et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858-62.
48. Davies KJ et al. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J. 1986;235(3):747-54.
49. Squadrito GL et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000;376(2):333-7.
50. Kaur H, Halliwell B. Action of biologically-relevant oxidizing species upon uric acid. Identification of uric acid oxidation products. Chem Biol Interact. 1990;73(2-3):235-47.
51. GlantzounisGK et al.Uric acid and oxidative stress. Curr PharmDes. 2005;11(32):4145-51.
52. Wlaschek M, Scharffetter-Kochanek K. Oxidative stress in chronic venous leg ulcers. Wound Repair Regen. 2005;13(5):452-61.
53. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal. 1999;11(1):1-14.
54. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82(1):47-95.
55. Fridovich I. Superoxide radicals, superoxide dismutases and the aerobic lifestyle. Photochem Photobiol. 1978;28(4-5):733-41.
56. Deby C, Goutier R. New perspectives on the biochemistry of superoxide anion and the efficiency of superoxide dismutases. Biochem Pharmacol. 1990;39(3):399-405.
57. Conner EM, Grisham MB. Inflammation, free radicals, and antioxidants. Nutrition. 1996;12(4):274-7.
58. Darr D, Fridovich I. Free radicals in cutaneous biology. J Invest Dermatol. 1994;102(5):671-5.
59. Finaud J, Lac G, Filaire E. Oxidative stress : relationship with exercise and training. Sports Med. 2006;36(4):327-58.
60. Valko M,Morris H, CroninMT.Metals, toxicity and oxidative stress. Curr Med Chem. 2005;12(10):1161-208.
61. Halliwell B, Gutteridge J. Free radicals in biology and medicine. Thirdth ed. New York: Oxford University Press Inc; 1999.
62. Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol. 2002;30(6):620-50.
63. Schreck R, Baeuerle PA. A role for oxygen radicals as second messengers. Trends Cell Biol. 1991;1(2-3):39-42.
64. Meyer M, Schreck R, Baeuerle PA. H2O2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. Embo J. 1993;12(5):2005-15.
65. Sun Y, Oberley LW. Redox regulation of transcriptional activators. Free Radic Biol Med. 1996;21(3):335-48.
66. Wenk J et al. Stable overexpression of manganese superoxide dismutase in mitochondria identifies hydrogen peroxide as a major oxidant in the AP-1-mediated induction of matrixdegrading metalloprotease-1. J Biol Chem. 1999;274(36): 25869-76.
67. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood. 1998;92(9):3007-17.
68. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther. 2006;111(1):16-26.
69. Weiss SJ et al. Oxidative autoactivation of latent collagenase by human neutrophils. Science. 1985;227(4688):747-9.
70. FuX et al. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001;276(44):41279-87.
71. Rayment EA, Upton Z, Shooter GK. Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br J Dermatol. 2008;158(5):951-61.
72. Hoyos B et al. Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science. 1989;244(4903):457- 60.
73. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol. 1990;10(5):2327-34.
74. Shakhov AN et al. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med. 1990;171(1):35-47.
75. Page S et al. Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. Biochim Biophys Acta. 1998;1381(2):191-202.
76. Paget MS, Buttner MJ. Thiol-based regulatory switches. Annu Rev Genet. 2003;37:91-121.
77. Moran LK, Gutteridge JM, Quinlan GJ. Thiols in cellular redox signalling and control. Curr Med Chem. 2001;8(7):763-72.
78. Hawkins CL, Pattison DI, Davies MJ. Hypochlorite-induced oxidation of amino acids, peptides and proteins. Amino Acids. 2003;25(3-4):259-74.
79. Winter J et al. Bleach activates a redox-regulated chaperone by oxidative protein unfolding. Cell. 2008;135(4):691-701.
80. Bindoli A, Fukuto JM, Forman HJ. Thiol chemistry in peroxidase catalysis and redox signaling. Antioxid Redox Signal. 2008;10(9): 1549-64.
81. Posnett J, Franks PJ. Skin Breakdown, The Silent Epidemic. London, UK: Smith and Nephew; 2007.
82. Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem. 2002;9(2):195-217.
83. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87-114.
84. Allopurinol Tablets USP, DailyMed Current Medication Information.
85. Sekundo W, Augustin AJ, Strempel I. Topical allopurinol or corticosteroids and acetylcysteine in the early treatment of experimental corneal alkali burns: a pilot study. Eur J Ophthalmol. 2002;12(5): 366-72.
86. Kitagawa J et al. Allopurinol gel mitigates radiation-induced mucositis and dermatitis. J Radiat Res (Tokyo). 2008;49(1):49-54.
87. Wu XWet al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34(1):78-84.